pimicotinib + gemcitabine + nab-paclitaxel + toripalimab

This is a **combination regimen** consisting of the following agents: - **Pimicotinib**: an orally administered, highly selective and potent small-molecule inhibitor of colony stimulating factor-1 receptor (CSF-1R), developed by Abbisko Therapeutics. It blocks the activity of CSF-1R, which is implicated in the growth of certain types of tumors, notably tenosynovial giant cell tumor (TGCT)[1][2][3][5]. - **Gemcitabine**: a small molecule antimetabolite chemotherapy that inhibits DNA synthesis, commonly used for various solid tumors, including pancreatic, lung, and breast cancers. - **Nab-paclitaxel**: an albumin-bound formulation of paclitaxel (a taxane chemotherapy), enhancing solubility and delivery, primarily used in cancers such as breast, pancreatic, and lung cancer. - **Toripalimab**: a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), stimulating immune-mediated antitumor response. This regimen potentially combines **targeted therapy (CSF-1R inhibition), cytotoxic chemotherapy, and immunotherapy (PD-1 blockade)**. Indications may include advanced or difficult-to-treat solid tumors, combining standard-of-care regimens with investigational targeted and immunotherapy agents; individual agents are mainly in oncology clinical use or late-stage development[1][2].